Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial.

Lucero MG, Nohynek H, Williams G, Tallo V, Simões EA, Lupisan S, Sanvictores D, Forsyth S, Puumalainen T, Ugpo J, Lechago M, de Campo M, Abucejo-Ladesma E, Sombrero L, Nissinen A, Soininen A, Ruutu P, Riley I, Mäkelä HP.

Pediatr Infect Dis J. 2009 Jun;28(6):455-62. doi: 10.1097/INF.0b013e31819637af.

PMID:
19483514
2.

IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.

Soininen A, Nohynek H, Lucero M, Jousimies K, Ugpo J, Williams G, Käyhty H; ARIVAC Consortium.

Vaccine. 2009 May 5;27(20):2680-8. doi: 10.1016/j.vaccine.2009.02.059. Epub 2009 Feb 24.

PMID:
19428879
3.

Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.

Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RA, Nohynek H, Riley ID, Makela H.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004977. doi: 10.1002/14651858.CD004977.pub2. Review.

PMID:
19821336
4.

Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.

Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Rodriguez M, Troitiño M, Carabajal C, Falaschi A, Leandro A, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L; COMPAS Group.

PLoS Med. 2014 Jun 3;11(6):e1001657. doi: 10.1371/journal.pmed.1001657. eCollection 2014 Jun. Erratum in: PLoS Med. 2015 Jun;12(6):e1001850.

PMID:
24892763
5.

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA; Gambian Pneumococcal Vaccine Trial Group.

Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46. Erratum in: Lancet. 2005 Jul 2-8;366(9479):28.

PMID:
15794968
6.

Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age.

Lucero MG, Dulalia VE, Parreno RN, Lim-Quianzon DM, Nohynek H, Makela H, Williams G.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004977. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004977.

PMID:
15495133
7.

Reactogenicity and tolerability of a non-adjuvanted 11-valent diphtheria-tetanus toxoid pneumococcal conjugate vaccine in Filipino children.

Ugpo J, Lucero M, Williams G, Lechago M, Nillos L, Tallo V, Nohynek H; Arivac Consortium.

Vaccine. 2009 May 5;27(20):2723-9. doi: 10.1016/j.vaccine.2008.10.026. Epub 2008 Oct 31.

PMID:
18977267
8.

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group.

N Engl J Med. 2003 Oct 2;349(14):1341-8.

PMID:
14523142
9.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.

Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3577-84. doi: 10.1016/j.vaccine.2013.04.085. Epub 2013 May 18.

PMID:
23688526
10.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3585-93. doi: 10.1016/j.vaccine.2013.05.010. Epub 2013 May 18.

PMID:
23688527
11.

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.

Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J.

Pediatr Infect Dis J. 2002 Sep;21(9):810-5.

PMID:
12352800
12.

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.

Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3594-602. doi: 10.1016/j.vaccine.2013.04.084. Epub 2013 May 18.

PMID:
23688525
13.

The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.

Trück J, Jawad S, Goldblatt D, Roalfe L, Snape MD, Voysey M, Pollard AJ.

Pediatr Infect Dis J. 2016 Jul;35(7):787-93. doi: 10.1097/INF.0000000000001180.

PMID:
27088583
14.

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.

McFetridge R, Meulen AS, Folkerth SD, Hoekstra JA, Dallas M, Hoover PA, Marchese RD, Zacholski DM, Watson WJ, Stek JE, Hartzel JS, Musey LK.

Vaccine. 2015 Jun 4;33(24):2793-9. doi: 10.1016/j.vaccine.2015.04.025. Epub 2015 Apr 23.

PMID:
25913828
15.

Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.

Nachman S, Kim S, King J, Abrams EJ, Margolis D, Petru A, Shearer W, Smith E, Moye J, Blanchard S, Hawkins E, Bouquin P, Vink P, Benson M, Estep S, Malinoski F; Pediatric AIDS Clinical Trials Group Study 292 Team.

Pediatrics. 2003 Jul;112(1 Pt 1):66-73.

PMID:
12837869
16.

Pneumococcal conjugate vaccine--a health priority.

Zar HJ, Madhi SA.

S Afr Med J. 2008 Jun;98(6):463-7.

PMID:
18683380
17.

Efficacy of different pneumococcal conjugate vaccine schedules against pneumonia, hospitalisation, and mortality: re-analysis of a randomised trial in the Gambia.

Mackenzie GA, Bottomley C, van Hoek AJ, Jeffries D, Ota M, Zaman SM, Greenwood B, Cutts F.

Vaccine. 2014 May 1;32(21):2493-500. doi: 10.1016/j.vaccine.2014.02.081. Epub 2014 Mar 11.

PMID:
24631086
18.

The worldwide impact of the seven-valent pneumococcal conjugate vaccine.

Fitzwater SP, Chandran A, Santosham M, Johnson HL.

Pediatr Infect Dis J. 2012 May;31(5):501-8. doi: 10.1097/INF.0b013e31824de9f6.

PMID:
22327872
19.

The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines.

Sanvictores DH, Lucero MG, Nohynek H, Tallo VL, Tanskanen A, Nillos LT, Williams G; ARIVAC Consortium.

BMC Res Notes. 2012 Jun 7;5:274. doi: 10.1186/1756-0500-5-274.

PMID:
22676626
20.

Distance to health services affects local-level vaccine efficacy for pneumococcal conjugate vaccine (PCV) among rural Filipino children.

Root ED, Lucero M, Nohynek H, Anthamatten P, Thomas DS, Tallo V, Tanskanen A, Quiambao BP, Puumalainen T, Lupisan SP, Ruutu P, Ladesma E, Williams GM, Riley I, Simões EA.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3520-5. doi: 10.1073/pnas.1313748111. Epub 2014 Feb 18.

PMID:
24550454

Supplemental Content

Support Center